je.st
news
Tag: merck
Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress 2014
2014-03-24 12:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Company to Initiate Phase 3 Clinical Development Program in Q2 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), also known as The International Liver Congress 2014. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
international
present
annual
Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT (vintafolide) and Companion Imaging Agents FOLCEPRI (etarfolatide) and NEOCEPRI (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...
2014-03-21 13:05:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind. WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT (vintafolide) and Companion Imaging Agents FOLCEPRI (etarfolatide) and NEOCEPRI (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer Language: English Contact: MerckMedia:Ian McConnell, +1 908-423-3046Claire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465Justin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292Tony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: in
with
positive
opinions
Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29
2014-03-20 22:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April 29. During the call, company executives will provide an overview of Mercks performance for the quarter. Language: English Contact: MerckMedia:Kelley Dougherty, 267-305-3552orSteven Cragle, 908-423-3461orInvestors:Carol Ferguson, 908-423-4465orJoe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Animal Health Launches Scholarship Program
2014-03-20 21:42:29| Beef
Merck Animal Health announced the recipients of the Merck Animal Health Veterinary Student Scholarship Program, awarding $100,000 in scholarships to 20 veterinary students. Through a partnership with the American Veterinary Medical Foundation (AVMF), the program recognizes outstanding second and third year students who are pursuing careers in large animal and companion animal medicine. read more
Tags: health
program
animal
launches
Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
2014-03-04 23:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
house
study
phase
Sites : [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] next »